Full-Spectrum CBD and Alcohol Craving: Why Less Craving Was Not Less Drinking
A small randomized trial found a favorable craving signal with full-spectrum CBD but no reduction in drinks per drinking day attributable to treatment. Reduced craving and reduced alcohol consumption were not interchangeable outcomes.
Three preparations were compared
Forty-four participants with moderate-to-severe alcohol use disorder were randomized to full-spectrum CBD, broad-spectrum CBD or placebo for eight weeks. The intended CBD intake was approximately 150 mg daily in the active groups.
The full-spectrum product contained a small amount of THC, while the broad-spectrum preparation did not. Other constituents also belonged to the actual product comparison; this was not a complete factorial experiment isolating every ingredient.
Preserve the null drinking finding
The full-spectrum group showed reductions in craving and selected disorder-symptom measures relative to the comparisons. However, the analysis did not find a significant treatment effect or time-by-treatment interaction on drinks per drinking day.
That distinction limits claims about clinical effectiveness. A questionnaire improvement cannot simply be converted into demonstrated lower alcohol exposure, fewer intoxication episodes or a reduction in injury risk.
A pilot signal does not prove synergy
The investigators found no significant between-group differences in attrition and side-effect analyses, but the groups were small. Failure to detect a safety difference is not proof that adverse effects are impossible.
The full-spectrum result also does not establish THC–CBD synergy. Dose-specific component comparisons and replication would be needed to identify that mechanism.
The study supports further investigation of defined formulations and outcomes. It does not establish a treatment recommendation for self-directed cannabis use in alcohol use disorder or certify the safety of combining alcohol with THC.
Related analysis
See our analysis of a separate laboratory question about combined THC and ethanol exposure.
Primary research
Raeghan L. Mueller and colleagues. A preliminary randomized trial of the safety, tolerability, and clinical effects of hemp-derived cannabidiol in alcohol use disorder. Frontiers in Psychiatry. DOI: 10.3389/fpsyt.2025.1516351.
